Instructions to Authors 2014

**General Policy.** ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrantee due diligence in the creation and issuance of their work.

**NIIH Open Access Policy.** The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

**Copyright.** Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

**Format.** Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

**Manuscripts.** Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) **First page** including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) **Abstract** not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) **Introduction**; (d) **Materials and Methods/Patients and Methods**; (e) **Results**; (f) **Discussion**; (g) **Acknowledgements**; (h) **References.** All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

**Figures.** All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

**Tables.** Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):
1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:
   John G. Delinasios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2014 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
Relationship Between EGFR Mutations and Clinicopathological Features of Lung Adenocarcinomas Diagnosed via Small Biopsies. H.J. KIM, E.Y. CHOI, H.J. JIN, K.-C. SHIN (Daegu, Republic of Korea) ....................... 3189

The Role of Sentinel Lymph Node Biopsy in Patients with Local Recurrence or In-Transit Metastasis of Melanoma. M. GIPPONI, N. SOLARI, D. GIOVINAZZO, P. QUEIROLO, S. BERTOGLIO, G. VILLA, M. GUALCO, D. BLEIDL, F. CAFIERO (Genoa, Italy) ........................................................................ 3197

Predictive Role of CEA and CYFRA 21-1 in Patients with Advanced-stage NSCLC Treated with Erlotinib. O. FIALA, M. PESEK, J. FINEK, L. BENESOVA, M. MINARIK, Z. BORTLICEK, O. TOPOLCAN (Prague; Brno, Czech Republic) ........................................................................................................... 3205


NAT2, XRCC1 and hOGG1 Polymorphisms, Cigarette Smoking, Alcohol Consumption and Risk of Upper Aerodigestive Tract Cancer. C.R. MARQUES, T.M. DA SILVA, D.M. DE ALBUQUERQUE, M.S. CHAVES, M.F. MARQUES FILHO, J.S. OLIVEIRA, G. DI PIETRO, S.M.B. SOUSA, A.L. SIMÕES, F. RIOS-SANTOS (Ilhéus; Jequié; Campinas; Lagarto; Vitória da Conquista; Ribeirão Preto; Cuiabá, Brazil) .............. 3217

Impact of Preoperative Thrombocytosis on Pathological Outcomes and Survival in Patients Treated with Radical Cystectomy for Bladder Carcinoma. M. MOSCHINI, N. SUARDI, F. PELLUCCHI, L. ROCCHINI, G. LA CROCE, U. CAPITANIO, A. BRIGANTI, R. DAMIANO, F. MONTORSI, R. COLOMBO (Milan; Reggio Emilia; Catanzaro, Italy) ............................................................ 3225

Errata ............................................................................................................................................ 3231

Book Reviews ................................................................................................................................ 3233

Announcements .............................................................................................................................. 3241

Intratumoral But Not Peritumoral Lymphatic Vessel Density Measured by D2-40 Expression Predicts Poor Outcome in Gastric Cancer – ROC Curve Analysis to Find Cut-off Point. P. DONIZY, J. RUDNO-RUDZINSKA, A. HALON, M. DZIEGALAJ, J. KABAROWSKI, E. FREJLICH, P. DZIEGIEL, W. KIELAN, R. MATKOWSKI (Wroclaw, Poland) ........................................... 3113

Histological Changes After Radiation Therapy in Patients with Lung Cancer: A Prospective Study. G. KARPATHIOU, A. GIATROMANOLAKI, M.I. KOUKOURAKIS, V. MIHAILIDIS, E. SIVRIDIS, D. BOUROS, M.E. FROUDARAKIS (Alexandroupolis, Greece) ................................................................. 3119

Gemcitabine-based Adjuvant Chemotherapy for Patients with Advanced Gallbladder Cancer. M. NAKAMURA, H. NAKASHIMA, T. ABE, T. ENSAKO, K. YOSHIDA, K. HINO (Kurashiki, Japan) .......... 3125

Glasgow Prognostic Score Is a Useful Predictive Factor of Outcome After Palliative Gastrectomy for Stage IV Gastric Cancer. K. MIMATSU, T. OIDA, N. FUUKINO, H. KANO, A. KAWASAKI, K. KIDA, Y. KUBOI, S. AMANO (Kanagawa; Tokyo, Japan) ................................................................. 3131

Prognostic Significance of Pre- and Postoperative Glasgow Prognostic Score for Patients with Non-small Cell Lung Cancer. M. TOMITA, T. AYABE, E. CHOSA, K. NAKAMURA (Kiyotake, Miyazaki, Japan) .................. 3137


Vascular Invasion, but not Lymphatic Invasion, of the Primary Tumor Is a Strong Prognostic Factor in Patients with Colorectal Cancer. T. FUJI, T. SUTOH, H. MORITA, R. YAJIMA, S. YAMAGUCHI, S. TSUTSUMI, T. ASAO, H. KUWANO (Maebashi, Gunma; Mibu, Tochigi, Japan) ................................................................. 3147

Excellent Prognosis of Lepidic-predominant Lung Adenocarcinoma: Low Incidence of Lymphatic Vessel Invasion as a Key Factor. K. ARAKI, Y. KIDOKORO, K. HOSOYA, M. WAKAHARA, Y. MATSUOKA, Y. TAKAGI, T. HARUKI, K. MIWA, Y. TANIGUCHI, S. HORIE, H. NAKAMURA (Yonago, Japan) ....................... 3153

Histological Growth Pattern of and Alpha-actinin-4 Expression in Thyroid Cancer. N. TANAKA, T. YAMASHITA, S. YAMAMOTO, T. MATSUBONBU, H. TSUDA, K. HONDA, T. YAMADA, S. TAMAI, A. SHIOTANI (Saitama; Tokyo, Japan) ........................................................................................................ 3157

Utility of Measuring Circulating Tumor Cell Counts to Assess the Efficacy of Treatment for Carcinomas of Unknown Primary Origin. K. KOMINE, M. INOUE, K. OTSUOKA, K. FUKUDA, H. NANJO, H. SHIBATA (Akita, Japan) ................................................................. 3165


Hypothyroidism as a Predictive Clinical Marker of Better Treatment Response to Sunitinib Therapy. D. KUST, M. PRPIC, J. MURGIĆ, M. JAZVIĆ, B. JAKŠIĆ, D. KRILIĆ, A. BOLANČA, Z. KUSIĆ (Zagreb, Croatia) ................................................................. 3177

Gefitinib and Afatinib Treatment in an Advanced Non-small Cell Lung Cancer (NSCLC) Patient Undergoing Hemodialysis. M. BERSANELLI, M. TISEO, F. ARTIOLI, L. LUCCHI, A. ARDIZZONI (Parma; Modena, Italy) ........................................................................................................ 3185

Contents continued on the preceding page
Insulin-like Growth Factor Receptor 1 mRNA Expression as a Prognostic Marker in Advanced Non-small Cell Lung Cancer. A. VILMAR, E. SANTONI-RUGIU, J. GARCIA-FONCILLAS, M. HUARRIZ, J.B. SØRENSEN (Copenhagen, Denmark; Pamplona, Spain) ................................................................. 2991

Preliminary Clinical Outcomes of Image-guided 3-Dimensional Conformal Radiotherapy for Limited Brain Metastases Instead of Stereotactic Irradiation Referral. K. OHTAKARA, H. HOSHI (Gifu; Seki, Gifu, Japan) ... 2997

An Additional Case of Gastric Serrated Adenoma. C.A. RUBIO, P.T. SCHMIDT (Stockholm, Sweden) .... 3007

Survival and Prognostic Factors in Pancreatic and Ampullary Cancer. J. LEMKE, D. SCHÄFER, S. SANDER, D. HENNE-BRUNS, M. KORNMA (Ulm, Germany) ..................................................... 3011

NF1 Truncating Mutations Associated to Aggressive Clinical Phenotype with Elephantiasis Neuromatosa and Solid Malignancies. G. PONTI, D. MARTORANA, G. PELLACANI, C. RUINI, P. LOSCHI, A. BACCARANI, G. DE SANTIS, A. POLLIO, T.M. NERI, V.D. MANDEL, A. MAJORANA, L. MACCIO, M. MACCAFERRI, A. TOMASI (Modena; Parma; Padova, Italy) ....................................................... 3021

XRCC1 rs25487 Polymorphism Predicts the Survival of Patients After Postoperative Radiotherapy and Adjutant Chemotherapy for Breast Cancer. M. TENGSTRÖM, A. MANNERMAA, V.-M. KOSMA, A. HIRVONEN, V. KATAJA (Kuopio; Helsinki, Finland) ........................................................................ 3031

Clinical Efficacy of Non-transplant Therapies in Patients with Hepatocellular Carcinoma with Child-Pugh C Liver Cirrhosis. H. NISHIKAWA, R. KITA, T. KIMURA, Y. OHARA, H. TAKEDA, A. SAKAMOTO, S. SAITO, N. NISHIJIMA, A. NASU, H. KOMEKADO, Y. OSAKI (Osaka-Sayama, Osaka, Japan) ... 3039

Clinical Trial of a 7-Peptide Cocktail Vaccine with Oral Chemotherapy for Patients with Metastatic Colorectal Cancer. K. OKUNO, F. SUGIURA, K. INOUE, Y. SUKEGAWA (Osaka, Japan) ........................................ 3045

Prognostic Significance of Urine N\textsubscript{1},N\textsubscript{12}-Diacytelspermine in Patients with Non-small Cell Lung Cancer. M. KATO, H. ONISHI, K. MATSUMOTO, J. MOTOSHITA, N. TSURUTA, K. HIGUCHI, M. KATANO (Fukuoka, Japan) ............................ 3053

Cell-Adhesion Molecule Expression and the Proliferation of Malignant Mesothelioma: A Post-Mortem Examination. K. KURIBAYASHI, H. HIRANO, K. NAKASHO, H. OHYAMA, K. YAMANEGI, C. TABATA, K. FUKUOKA, Y. FUJIMORI, T. NAKANO (Gifu; Osaka; Hyogo, Japan) ... 3061

Long-term Follow-up of Intermediate-risk Non-muscle Invasive Bladder Cancer Sub-classified by Multi-coloured FISH. C. MIAN, E. COMPOJLO, E. RESNYAK, E. TRENTI, S. PALERMO, M. LODDE, A. PYCHA, A. AMBROSINI-SPALITRO, C.B. DECHET, A. PYCHA (Bolzano, Italy; Riga, Latvia; Salt Lake City, UT, USA) ......................................................... 3067

Atypical Lipomatous Tumor with Structural Rearrangements Involving Chromosomes 3 and 8. J. NISHIO, H. IWASAKI, M. NABESIMA, Y. KAMACHI, M. NAITO (Fukuoka, Japan) .......................... 3073

Role of Novel Risk Classification Method, Prostate Cancer Risk Index (PRIX) for Clinically Localized Prostate Cancer After Highdose-rate Interstitial Brachytherapy as Monotherapy. K. YOSHIDA, H. YAMAZAKI, S. NAKAMURA, K. MASUI, T. KOTSUMA, H. AKIYAMA, E. TANAKA, Y. YOSHIKA (Tokatsuki; Suita, Osaka; Kyoto, Japan) ......................................................... 3077


Contents continued on the preceding page

Effects of Targeting Endometrial Stromal Sarcoma Cells via Histone Deacetylase and PI3K/AKT/mTOR Signaling. P. QUAN, F. MOINFAR, I. KUFFERATH, M. ABSENGER, T. KUEZNICK, H. DENK, K. ZATLOUKAL, J. HAYBAECK (Graz; Linz, Austria) ................................................................. 2883


Cell-cycle Distribution and Thymidilate Synthetase (TS) Expression Correlate with 5-FU Resistance in Head and Neck Carcinoma Cells. K. IJICHI, M. ADACHI, T. OGAWA, Y. HASEGAWA, S. MURAKAMI (Nagoya; Nagakute, Aichi; Gifu, Japan) ............................................................................................ 2907

Effect of EPH–Ephrin Signaling on the Growth of Human Leukemia Cells. Y. TAKAHASHI, M. ITOH, N. NARA, S. TOHDA (Tokyo, Japan) .................................................................................................... 2913

PPM1D as a Novel Biomarker for Prostate Cancer After Radical Prostatectomy. L. JIAO, D. SHEN, G. LIU, J. JIA, J. GENG, H. WANG, Y. SUN (Shanghai; Changchun, Jilin, PR China) ................................................................. 2919

RAD001 Enhances the Radiosensitivity of SCC4 Oral Cancer Cells by Inducing Cell Cycle Arrest at the G2/M Checkpoint. C.-C. YU, S.-K. LING, H.-F. LIAO, C.-C. LEE, H.-Y. LIN, H.-C. LAI, S.-C. LI, H.-C. HO, H.-B. HUANG, Y.-C. SU (Chiayi; Hualien; Taipei, Taiwan, ROC) ................................................................. 2927

Pattern of Somatostatin Receptors Expression in Normal and Bladder Cancer Tissue Samples. M. KARAVITAKIS, P. MSAOUEL, V. MICHALOPOULOS, M. KOUTSILIERIS (Athens, Greece; Bronx, NY, USA) .................................................................................................................. 2937


The Steroidal Na+/K+ ATPase Inhibitor 3-[(R)-3-Pyrrolidinyl]oximeDerivative (3-R-POD) Induces Potent Pro-Apoptotic Responses in Colonic Tumor Cells. S.H. ALKAHTANI (Riyadh, Saudi Arabia) ................................................................. 2967

FIP-gts Potentiate Autophagic Cell Death Against Cisplatin-resistant Urothelial Cancer Cells. J.-R. LI, C.-L. CHENG, W.-J. YANG, C.-R. YANG, Y.-C. OU, M.-J. WU, J.-L. KO (Taichung, Taiwan, ROC) ................................................................. 2973

Clinical Studies

DNA Methylation in Paired Breast Epithelial and White Blood Cells from Women Undergoing Reduction Mammoplasty. S.R. STURGEON, K.F. ARCARO, M.A. JOHNSON, R. BALASUBRAMANIAN, M. ZORN, D.J. JERRY, S. SMITH SCHNEIDER (Amherst; Springfield, MA, USA) ................................................................. 2985

Contents continued on the preceding page
Collaborative Network of Predictive Markers Complicates Formation of Prognostic Groups in Patients with Advanced Lung Cancer. B. SCHWAB, A. RUDOLPH, E. JOST, U. KLINGE (Aachen; Neubiberg, Germany) ...


The Role of Type D Prostanoid Receptors and PPARγ in Gastric Cancer Progression. T. FUKUOKA, M. YASHIRO, T. MORISAKI, H. KINOSHITA, T. HASEGAWA, H. KASASHIMA, G. MASUDA, K. SAKURAI, T. TOYOKAWA, H. TANAKA, N. KUBO, K. MUGURUMA, M. OHIRA, K. HIRAKAWA (Osaka, Japan) ...


Heparanase and COX-2 Expression as Predictors of Lymph Node Metastasis in Large, High-grade Breast Tumors. S. GAWTHORPE, J.E. BROWN, M. ARIF, P. NIGHTINGALE, A. NEVILL, A.R. CARMICHAEL (Birmingham; Walsall; Dudley, UK) ........................................................................................................................................

Predicting the Sensitivity to Ion Therapy Based on the Response to Photon Irradiation – Experimental Evidence and Mathematical Modelling. C. MOHANTY, K. ZIELINSKA-CHOMEJ, M. EDGREN, R. HIRAYAMA, T. MURAKAMI, B. LIND, I. TOMA-DASU (Stockholm, Sweden; Chiba, Japan) ..............................................

Development of a Dihydroartemisinin-resistant Molt-4 Leukemia Cell Line. J. PARK, H.C. LAI, M. SINGH, T. SASAKI, N.P. SINGH (Seattle, WA, USA) ........................................................................

Influence of Hypoxia Inducible Factors on the Immune Microenvironment in Ovarian Cancer. M. DUECHLER, L. PE CZEK, M. SZUBERT, J. SUZIN (Lodz, Poland) ..........................................................

SOD3 Acts as a Tumor Suppressor in PC-3 Prostate Cancer Cells via Hydrogen Peroxide Accumulation. J. KIM, A. MIZOKAMI, M. SHIN, K. IZUMI, H. KONAKA, Y. KADONO, Y. KITAGAWA, E.T. KELLER, J. ZHANG, M. NAMIKI (Kanazawa, Ishikawa, Japan; Ann Arbor, MI, USA; Nanning, Guangxi, China) ........

HSPA2 Is Expressed in Human Tumors and Correlates with Clinical Features in Non-small Cell Lung Carcinoma Patients. D. SCIEGLINSKA, A. GOGLER-PIGLÓWSKA, D. BUTKIEWICZ, M. CHEKAN, E. MALUSECKA, J. HARASIM, A. HABRYKA, Z. KRAWCZYK (Gliwice; Zabrze, Poland) .........................

Primary and Secondary Resistance to Tyrosine Kinase Inhibitors in Lung Cancer. J. SIMASI, A. SCHUBERT, C. OELKRUG, A. GILLISSEN, K. NIEBER (Leipzig; Kassel, Germany) ........................................

The Role of Claudin-1 and Claudin-7 in Cervical Tumorigenesis. C. CUNNiffe, B. BRANKIN, H. LAMBKIN, F. RYAN (Dublin, Ireland) .................................................................................................................................

Spontaneous In Vitro Senescence of Glioma Cells Confirmed by an Antibody Against IDH1R132H. E. STOCZYNSKA-FIDELUS, W. OCH, P. RIESKE, M. BIENKOWSKI, M. BANASZCZYK, M. WINECKA-KLIMEK, J. ZIEBA, K. JANIK, K. ROŠIAK, C. TRED A, R. STAWSKI, A. RADOMI AK-ZALUSKA, S. PIASKOWSKI (Lodz; Olsztyn; Zgierz, Poland) ..................................................